Tag: KRAS G12C colorectal cancer

Home / KRAS G12C colorectal cancer

Categories

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

  June 2024: The Food and Drug Administration has given accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) in combination with cetuximab for adults who have KRAS G12C-mutat...
kras-g12c-colorectal-cancer

Scan the code